|
Market Closed -
Nasdaq
16:00:00 2026-09-03 EDT
|
5-day change | 1st Jan Change | ||
| 2.140 USD | 0.00% |
|
-0.47% | -38.15% |
| 08-24 | Grace Therapeutics Files for Resale of Up to 4.8 Million Shares | MT |
| 08-13 | Grace Therapeutics, Inc. Reports Impairment charges for the First Quarter Ended June 30, 2026 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| GRACE THERAPEUTICS, INC. | Bio Therapeutic Drugs | 0.00% | -0.47% | -38.15% | -28.43% | -85.96% | 45.02M |  |  | |
- Stock Market
- Stocks
- GRCE Stock
- Charts Grace Therapeutics, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
